Insights
Insights From Our Experts
Articles
The Evolving Role of Pharma 3PLs To Drive Value & Impact
Danny Williams, President of Channel Management & 3PL at EVERSANA, recently sat down Pharmaceutical Commerce for a series of interviews on the state of pharm 3PLs and logistics. He discussed the role of today’s logistics partners…
The Real Cost of Delayed Pharmacovigilance (PV) Launch Readiness
What is the real cost of delayed Pharmacovigilance (PV) launch readiness? Most pharmaceutical launch delays and failures are not driven by clinical setbacks but are caused by hidden gaps in commercial compliance readiness. There are four predictable, high-stakes moments…
Avoiding the Top 3 Pharmacovigilance Mistakes
FDA approval is a monumental milestone for any emerging pharma or biotech company. However, for first-time sponsors, ringing the bell on approval is just the beginning. The transition into maintaining an operationally critical, inspection-ready Pharmacovigilance (PV) function is a…
What’s Trending in Oncology? A Discussion Following ASCO 2026 with Anne Marie Robertson
Following ASCO 2026, one message is clear: innovation in oncology is accelerating and the complexity of bringing these therapies to market is evolving just as quickly. In a recent Q&A with Pharmaceutical Executive, Anne Marie Robertson,…
Winning in the EU JCA Era: Why Proactive Intelligence Will Define Market Access Success
The EU JCA Is Changing the Rules of Market Access The EU Joint Clinical Assessment (JCA) is not simply another regulatory milestone; it represents a fundamental transformation in how clinical evidence will be evaluated, aligned, and…
Why Humans Must Be Part of the Bigger AI Picture
As AI reshapes how work gets done across industries, all organizations including life sciences are being challenged to balance speed, scale, and innovation with something equally critical: trust. Faruk Capan, Chief Innovation Officer at EVERSANA, explores…
You Cannot Commercialize What is Not Compliant
Most launch delays don’t start in the clinic, but rather stem from overlooked gaps in commercial compliance. Complete Response Letters (CRLs), though one of the greatest threats to launch success, are largely preventable with the proper…
EVERSANA Back as Global Host and Presenting Sponsor for Frontiers Health 2026
EVERSANA will return as Global Host and Presenting Sponsor of Frontiers Health 2026, taking place in Berlin on October 20–21. As one of the premier events for the global health innovation ecosystem, Frontiers Health brings together…
The Stability Advantage: Why Revenue Protection is the New Standard in Commercial Deployment
Is your commercial field force truly operating at full capacity? Even when a team boasts 100% headcount, the reality is that true productivity rarely matches that number. Organizations are quietly forfeiting revenue, not just to market competitors, but to the continuous…
The Indispensable Edge: Why the EVERSANA AI Agency Platform is a Must-Have for Expert Oncology Marketers
The oncology landscape is more complex, specialized, and competitive than ever before. To succeed in this data-driven world, expert oncology marketers need more than just traditional strategies— they need an intelligent approach to commercialization, launch readiness,…